Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Greenyn Biotechnology Co., Ltd. (6846:TWSE), powered by AI.
Greenyn Biotechnology Co., Ltd. is currently trading at $67.30. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Greenyn Biotechnology Co., Ltd. on Alpha Lenz.
View Greenyn Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.
“Greenyn Biotechnology Co., Ltd.'s ROE is 15.9%. Explore profitability and growth together.”
Ask for details →Greenyn Biotechnology Co., Ltd. is a biotechnology company specializing in the research, development, manufacturing, and sale of health food raw materials and dietary supplements. Established in 2012 and headquartered in Taichung, Taiwan, the company focuses on innovative functional ingredients such as solid-state antrodia cinnamomea mycelia, bitter gourd peptide, and a comprehensive vegetable and fruit fermentation broth. Its proprietary product lines, including branded ingredients like Insumate, Antromax, and Zymologist 101, serve a diverse range of health needs, encompassing metabolic health, digestive support, immunity, youth and beauty, and specialized formulations for various life stages and health concerns. Greenyn’s portfolio features a wide array of functional formulas targeting digestion, brain health, energy, circulation, immune modulation, and more, making it a notable supplier to both domestic and international markets. The company is recognized for its R&D achievements, such as award-winning patented plant extracts, and plays a vital role in supporting the health technology and biotechnology sectors through extensive OEM/ODM services and global partnerships.
“Greenyn Biotechnology Co., Ltd.'s ROE is 15.9%. Explore profitability and growth together.”
Ask for details →Greenyn Biotechnology Co., Ltd. (ticker: 6846) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 67.3 with a P/E ratio of -x and P/B of -x.
ROE is 15.90% and operating margin is 20.63%. Annual revenue is $915M.